Hyresintäkterna uppgick till 865 mkr, i linje med motsvarande kvartal föregående år.
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe , the...
Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint ...
AVTECH presented its Q1 2025 figures, which closely aligned with Redeye’s projections for net sales,...
Last evening, Enviro announced it had resolved a partially guaranteed rights issue of units of appro...
Q1e: a solid quarter with EBITA up 11% y-o-y Higher estimates following ambitious new targets Medica...
Redeye has revised its estimates for CoinShares in anticipation of its Q1 2025 report, scheduled for...
Ahead of CapMan's Q1 2025 report due on 9 May, we revise our estimates to reflect expected fair valu...
Katalysen Ventures investerar i små onoterade nordeuropeiska bolag genom sitt investeringsramverk Ve...
Q-linea achieved its objective with five ASTar contracts during Q1, supported by a much-improved pip...
Redeye retains its positive view of Carasent following the Q1 report.
Fiskars is highly exposed to the US through Fiskars BA.
Q1'25e organic sales growth of 47% y-o-y Minor estimate changes FVR of SEK 30-45 reiterated What to...
Redeye provides an in-depth review of Episurf Medical’s Q1 report and events during and after the qu...
Redeye comments on OncoZenge’s announcement of an exclusive licensing agreement with Avernus Pharma ...
Slightly softer sales and outlook (-5% vs. ABGSCe in Q4) We cut '25e-'26e sales by 9-8%, EBIT 24-15%...
Redeye offers a preview of Polygien's Q1 results set to be released on April 24.
Redeye updates on Invisio ahead of Q1-results (due 6 May) where we expect continued solid YoY growth...
Redeye provides a brief comment on Smart Eye’s newly proposed long-term incentive program for employ...
Incap had already anticipated a slow start for 2025, and now the entire EMS sector is holding its br...